These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20842046)

  • 1. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor.
    Cerasola G; Cottone S; Mulè G
    J Hypertens; 2010 Dec; 28(12):2357-69. PubMed ID: 20842046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.
    Mulè G; Castiglia A; Cusumano C; Scaduto E; Geraci G; Altieri D; Di Natale E; Cacciatore O; Cerasola G; Cottone S
    Adv Exp Med Biol; 2017; 956():279-306. PubMed ID: 27873229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microalbuminuria as an early marker for cardiovascular disease.
    de Zeeuw D; Parving HH; Henning RH
    J Am Soc Nephrol; 2006 Aug; 17(8):2100-5. PubMed ID: 16825327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microalbuminuria in essential hypertension.
    Crippa G
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S74-7. PubMed ID: 11986900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microalbuminuria and cardiovascular disease.
    Weir MR
    Clin J Am Soc Nephrol; 2007 May; 2(3):581-90. PubMed ID: 17699466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria.
    Pontremoli R; Leoncini G; Viazzi F; Ratto E; Vaccaro V; Falqui V; Parodi A; Conti N; Tomolillo C; Deferrari G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S112-4. PubMed ID: 16565232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria.
    Huang PH; Huang SS; Chen YH; Lin CP; Chiang KH; Chen JS; Tsai HY; Lin FY; Chen JW; Lin SJ
    J Hypertens; 2010 Aug; 28(8):1655-65. PubMed ID: 20520578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the use of urinary albumin as marker of kidney involvement in unselected populations.
    McQueen MJ
    Scand J Clin Lab Invest Suppl; 2008; 241():52-6. PubMed ID: 18569965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary albumin and cardiovascular profile in the middle-aged population.
    Cirillo M; Lombardi C; Bilancio G; Chiricone D; Stellato D; De Santo NG
    Semin Nephrol; 2005 Nov; 25(6):367-71. PubMed ID: 16298257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Microalbuminuria and urinary albumin excretion: French guidelines].
    Halimi JM; Hadjadj S; Aboyans V; Allaert FA; Artigou JY; Beaufils M; Berrut G; Fauvel JP; Gin H; Nitenberg A; Renversez JC; Rusch E; Valensi P; Cordonnier D;
    Ann Biol Clin (Paris); 2008; 66(3):277-84. PubMed ID: 18558566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of microalbuminuria as a cardiovascular risk indicator: A review.
    Diercks GF; van Boven AJ; Hillege JL; de Jong PE; Rouleau JL; van Gilst WH
    Can J Cardiol; 2002 May; 18(5):525-35. PubMed ID: 12032579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality.
    Klausen KP; Parving HH; Scharling H; Jensen JS
    J Intern Med; 2007 Oct; 262(4):470-8. PubMed ID: 17875184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
    Erdmann E
    Int J Cardiol; 2006 Feb; 107(2):147-53. PubMed ID: 15975669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic pathogenesis of cardiorenal disease.
    Keane WF
    Am J Kidney Dis; 2001 Dec; 38(6):1372-5. PubMed ID: 11728977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microalbuminuria and hypertension.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Minerva Med; 2005 Aug; 96(4):261-75. PubMed ID: 16179893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microalbuminuria and progressive renal disease.
    Kilaru P; Bakris GL
    J Hum Hypertens; 1994 Nov; 8(11):809-17. PubMed ID: 7853323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microalbuminuria: a marker of cardiovascular risk and organ damage in essential hypertension.
    Pontremoli R; Viazzi F; Sofia A; Tomolillo C; Ruello N; Bezante GP; Del Sette M; Martinoli C; Lotti R; Sacchi G; Deferrari G
    Kidney Int Suppl; 1997 Dec; 63():S163-5. PubMed ID: 9407448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria and cardiovascular risk.
    Karalliedde J; Viberti G
    Am J Hypertens; 2004 Oct; 17(10):986-93. PubMed ID: 15485765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors.
    Heo NJ; Ahn JM; Lee TW; Chin HJ; Na KY; Chae DW; Kim S
    Hypertens Res; 2010 Jun; 33(6):573-8. PubMed ID: 20379188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.